期刊文献+

双膦酸盐类药物不良反应及应用评价 被引量:13

ADRs Induced by Diphosphonate and Notice in the Application of Diphosphonate
下载PDF
导出
摘要 目的:双膦酸盐类(Diphosphonate)药物是近年发展起来的一类抗代谢性骨病新药,主要用于骨质疏松症、恶性肿瘤骨转移及高钙血症等。虽然此类药物产生的不良反应大部分是较轻微的,且是暂时性的。但随着其应用的日益广泛,该类药物对胃肠道、眼部、颚骨坏死、肌肉骨骼疼痛及肾脏等一些严重不良反应已引起人们的关注。本文对其不良反应与应用进行阐述和评价。方法:采用国内外文献检索方法。结果及结论:在临床上预防双膦酸盐类药物的不良反应,使患者更好地配合治疗,以达到最佳疗效。 OBJECTIVE:Diphosphonate, a newly developed drug for treating metabolic bone diseases such osteoporosis, malignant tumor osseous metastasis, hypercalcemia and so on. Most of the side effects of this agent are mild and temporary; however, with the increasingly widespread use of this agent, the serious adverse reactions (ADRs)occurred in organs such as gastrointestinal tract, ocular region, mandible (osteonecrosis of jawbone), skeletal musculature (myosalgia and ostalgia), kidney and so on have gained great attention in the clinic. This paper reviewed pertinent literature about the ADRs of diphosphonate to provide reference for clinical rational use of this drug. To describe the adverse drug reaction and to eveluate the use of diphosphonate. METHODS:To collecte medical literatures in recent years at home and abroad. RESULTS & CONCLUSION: To ensure maximal therapeutic effects, the ADRs of diphosphonate should be preevented in clinic.
出处 《中国医院用药评价与分析》 2008年第5期325-327,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 双膦酸盐类 不良反应 合理应用 Diphosphonate Adverse drug reaction Rational use
  • 相关文献

参考文献29

  • 1Licata AA. Discovery, clinical development and therapeutic uses of bisphosphonates [ J ]. Ann Pharmacother, 2005, 39 (4) :668.
  • 2Berenson JR. Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases [J]. The Oncologist, 2005, 10(1 ) :52.
  • 3Rosen LS, Gordon D, Kaminski M, et al. Long - term efficacy and safety of zoledronic acid compared with pamidronate disodium in tbe treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double - blind, multicenter, comparative trial [J]. Cancer, 2003, 98(8):1 735.
  • 4Small E J, Smith MR, Seaman JJ, et al. Combined Analysis of Two Multicenter, Randomized, Placebo - Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer [ J]. J Clin Oncol, 2003, 21(23) :4 277.
  • 5Major P, Lortholary A, Hon J, et al. Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy : A Pooled Analysis of Two Randomized, Controlled Clinical Trials [J]. J Clin O ncol, 2001, 19(2) :558.
  • 6Lin JH. Bisphosphonates: a review of their pharmacokinetic properties [J]. Bone, 1996, 18(2):75.
  • 7许重远,贾江滨.双膦酸盐类药物的临床应用进展[J].中国药学杂志,1999,34(7):433-435. 被引量:12
  • 8傅得兴,孙忠实,李豫.双膦酸盐类药物进展[J].中国新药杂志,1999,8(6):371-374. 被引量:18
  • 9Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid - related upper gastrointestinal disorders in women using alendronate for osteoporosis [ J]. Am J Manag Care, 1998, 4(10):1 377.
  • 10Peter CP, Kindt MV, Majka JA. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats [J] .Dig Dis Sci, 1998, 43 (5):1 009.

共引文献26

同被引文献116

引证文献13

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部